Evidence for the elevation of serum carcinoembryonic antigen and tumor associated glycoprotein-72 levels in patients administered interferons

Sera were collected from 111 patients diagnosed with adenocarcinoma or nonadenocarcinoma malignancies who received different schedules of interferon (IFN)-gamma or IFN-beta ser alone or in combination. Serum carcinoembryonic antigen (CEA) and tumor-associated glycoprotein-72 (TAG-72) antigen levels...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 1991-08, Vol.51 (16), p.4155-4163
Hauptverfasser: GREINER, J. W, GUADAGNI, F, GOLDSTEIN, D, BORDEN, E. C, RITTS, R. E, WITT, P, LOBUGLIO, A. F, SALEH, M. N, SCHLOM, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4163
container_issue 16
container_start_page 4155
container_title Cancer research (Chicago, Ill.)
container_volume 51
creator GREINER, J. W
GUADAGNI, F
GOLDSTEIN, D
BORDEN, E. C
RITTS, R. E
WITT, P
LOBUGLIO, A. F
SALEH, M. N
SCHLOM, J
description Sera were collected from 111 patients diagnosed with adenocarcinoma or nonadenocarcinoma malignancies who received different schedules of interferon (IFN)-gamma or IFN-beta ser alone or in combination. Serum carcinoembryonic antigen (CEA) and tumor-associated glycoprotein-72 (TAG-72) antigen levels were measured to determine whether interferon could enhance the tumor shedding and, thereby, the serum level of either tumor antigen. Less than 10% of the sera samples from patients diagnosed with nonadenocarcinoma malignancies (e.g., hairy cell leukemia, melanoma) had positive titers of TAG-72 or CEA, and interferon neither increased nor resulted in the appearance of either tumor antigen in those sera. In contrast, 59.2% and 75.4% of the patients with adenocarcinoma had positive serum levels of TAG-72 and CEA, respectively, prior to interferon. IFN-gamma and IFN-beta ser alone or in combination significantly increased serum TAG-72 or CEA in approximately 65% of those patients. The results suggest that interferon administration to patients with adenocarcinoma can result in increased serum levels of selected tumor-associated antigens used in the diagnosis of malignancy. These preliminary findings may be important in the development of new strategies to obtain more sensitive tumor antigen serum assays for the diagnosis and monitoring for disease progression of adenocarcinoma.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_80732868</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80732868</sourcerecordid><originalsourceid>FETCH-LOGICAL-h300t-ab511edc5582f08f6f7ea135570200da037d5bdc8ea74daf01d7e3c07bd2c3af3</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhhdRaq3-BCEH8baQbDZNepTiFxS86LnMJpM2spvUJFvoj_A_G3Dx6ulheJ95GeasmjPBVS3bVpxXc0qpqkUrm8vqKqXPMgpGxayasRWVSrF59f14dAa9RmJDJHmPBHs8QnbBk2BJwjgOREPUzgccungK3mkCPrsd-kJD8jiUTUgpaAcZDdn1Jx0OMWR0vpYNKX3YJ-I8OZRe9DkRMIPzLmWMxXe-0GIMPl1XFxb6hDcTF9XH0-P7-qXevD2_rh829Z5TmmvoBGNotBCqsVTZpZUIjAshaUOpAcqlEZ3RCkG2BixlRiLXVHam0RwsX1T3v73lzK8RU94OLmnse_AYxrRVVPJGLdW_IlsywZaCFvF2EsduQLM9RDdAPG2nR5f8bsohaehtBK9d-tPaVSs44_wHF46Lew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16151650</pqid></control><display><type>article</type><title>Evidence for the elevation of serum carcinoembryonic antigen and tumor associated glycoprotein-72 levels in patients administered interferons</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>GREINER, J. W ; GUADAGNI, F ; GOLDSTEIN, D ; BORDEN, E. C ; RITTS, R. E ; WITT, P ; LOBUGLIO, A. F ; SALEH, M. N ; SCHLOM, J</creator><creatorcontrib>GREINER, J. W ; GUADAGNI, F ; GOLDSTEIN, D ; BORDEN, E. C ; RITTS, R. E ; WITT, P ; LOBUGLIO, A. F ; SALEH, M. N ; SCHLOM, J</creatorcontrib><description>Sera were collected from 111 patients diagnosed with adenocarcinoma or nonadenocarcinoma malignancies who received different schedules of interferon (IFN)-gamma or IFN-beta ser alone or in combination. Serum carcinoembryonic antigen (CEA) and tumor-associated glycoprotein-72 (TAG-72) antigen levels were measured to determine whether interferon could enhance the tumor shedding and, thereby, the serum level of either tumor antigen. Less than 10% of the sera samples from patients diagnosed with nonadenocarcinoma malignancies (e.g., hairy cell leukemia, melanoma) had positive titers of TAG-72 or CEA, and interferon neither increased nor resulted in the appearance of either tumor antigen in those sera. In contrast, 59.2% and 75.4% of the patients with adenocarcinoma had positive serum levels of TAG-72 and CEA, respectively, prior to interferon. IFN-gamma and IFN-beta ser alone or in combination significantly increased serum TAG-72 or CEA in approximately 65% of those patients. The results suggest that interferon administration to patients with adenocarcinoma can result in increased serum levels of selected tumor-associated antigens used in the diagnosis of malignancy. These preliminary findings may be important in the development of new strategies to obtain more sensitive tumor antigen serum assays for the diagnosis and monitoring for disease progression of adenocarcinoma.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 1907881</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adenocarcinoma - blood ; Adenocarcinoma - immunology ; Adenocarcinoma - therapy ; Antigens, Neoplasm - analysis ; Antineoplastic agents ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Carcinoembryonic Antigen - analysis ; Female ; Glycoproteins - analysis ; Humans ; Immunotherapy ; Interferon Type I - therapeutic use ; Interferon-gamma - therapeutic use ; Medical sciences ; Neoplasms - blood ; Neoplasms - immunology ; Neoplasms - therapy ; Pharmacology. Drug treatments</subject><ispartof>Cancer research (Chicago, Ill.), 1991-08, Vol.51 (16), p.4155-4163</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4945313$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1907881$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GREINER, J. W</creatorcontrib><creatorcontrib>GUADAGNI, F</creatorcontrib><creatorcontrib>GOLDSTEIN, D</creatorcontrib><creatorcontrib>BORDEN, E. C</creatorcontrib><creatorcontrib>RITTS, R. E</creatorcontrib><creatorcontrib>WITT, P</creatorcontrib><creatorcontrib>LOBUGLIO, A. F</creatorcontrib><creatorcontrib>SALEH, M. N</creatorcontrib><creatorcontrib>SCHLOM, J</creatorcontrib><title>Evidence for the elevation of serum carcinoembryonic antigen and tumor associated glycoprotein-72 levels in patients administered interferons</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Sera were collected from 111 patients diagnosed with adenocarcinoma or nonadenocarcinoma malignancies who received different schedules of interferon (IFN)-gamma or IFN-beta ser alone or in combination. Serum carcinoembryonic antigen (CEA) and tumor-associated glycoprotein-72 (TAG-72) antigen levels were measured to determine whether interferon could enhance the tumor shedding and, thereby, the serum level of either tumor antigen. Less than 10% of the sera samples from patients diagnosed with nonadenocarcinoma malignancies (e.g., hairy cell leukemia, melanoma) had positive titers of TAG-72 or CEA, and interferon neither increased nor resulted in the appearance of either tumor antigen in those sera. In contrast, 59.2% and 75.4% of the patients with adenocarcinoma had positive serum levels of TAG-72 and CEA, respectively, prior to interferon. IFN-gamma and IFN-beta ser alone or in combination significantly increased serum TAG-72 or CEA in approximately 65% of those patients. The results suggest that interferon administration to patients with adenocarcinoma can result in increased serum levels of selected tumor-associated antigens used in the diagnosis of malignancy. These preliminary findings may be important in the development of new strategies to obtain more sensitive tumor antigen serum assays for the diagnosis and monitoring for disease progression of adenocarcinoma.</description><subject>Adenocarcinoma - blood</subject><subject>Adenocarcinoma - immunology</subject><subject>Adenocarcinoma - therapy</subject><subject>Antigens, Neoplasm - analysis</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoembryonic Antigen - analysis</subject><subject>Female</subject><subject>Glycoproteins - analysis</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Interferon Type I - therapeutic use</subject><subject>Interferon-gamma - therapeutic use</subject><subject>Medical sciences</subject><subject>Neoplasms - blood</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Pharmacology. Drug treatments</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LAzEQhhdRaq3-BCEH8baQbDZNepTiFxS86LnMJpM2spvUJFvoj_A_G3Dx6ulheJ95GeasmjPBVS3bVpxXc0qpqkUrm8vqKqXPMgpGxayasRWVSrF59f14dAa9RmJDJHmPBHs8QnbBk2BJwjgOREPUzgccungK3mkCPrsd-kJD8jiUTUgpaAcZDdn1Jx0OMWR0vpYNKX3YJ-I8OZRe9DkRMIPzLmWMxXe-0GIMPl1XFxb6hDcTF9XH0-P7-qXevD2_rh829Z5TmmvoBGNotBCqsVTZpZUIjAshaUOpAcqlEZ3RCkG2BixlRiLXVHam0RwsX1T3v73lzK8RU94OLmnse_AYxrRVVPJGLdW_IlsywZaCFvF2EsduQLM9RDdAPG2nR5f8bsohaehtBK9d-tPaVSs44_wHF46Lew</recordid><startdate>19910815</startdate><enddate>19910815</enddate><creator>GREINER, J. W</creator><creator>GUADAGNI, F</creator><creator>GOLDSTEIN, D</creator><creator>BORDEN, E. C</creator><creator>RITTS, R. E</creator><creator>WITT, P</creator><creator>LOBUGLIO, A. F</creator><creator>SALEH, M. N</creator><creator>SCHLOM, J</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19910815</creationdate><title>Evidence for the elevation of serum carcinoembryonic antigen and tumor associated glycoprotein-72 levels in patients administered interferons</title><author>GREINER, J. W ; GUADAGNI, F ; GOLDSTEIN, D ; BORDEN, E. C ; RITTS, R. E ; WITT, P ; LOBUGLIO, A. F ; SALEH, M. N ; SCHLOM, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h300t-ab511edc5582f08f6f7ea135570200da037d5bdc8ea74daf01d7e3c07bd2c3af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Adenocarcinoma - blood</topic><topic>Adenocarcinoma - immunology</topic><topic>Adenocarcinoma - therapy</topic><topic>Antigens, Neoplasm - analysis</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoembryonic Antigen - analysis</topic><topic>Female</topic><topic>Glycoproteins - analysis</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Interferon Type I - therapeutic use</topic><topic>Interferon-gamma - therapeutic use</topic><topic>Medical sciences</topic><topic>Neoplasms - blood</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GREINER, J. W</creatorcontrib><creatorcontrib>GUADAGNI, F</creatorcontrib><creatorcontrib>GOLDSTEIN, D</creatorcontrib><creatorcontrib>BORDEN, E. C</creatorcontrib><creatorcontrib>RITTS, R. E</creatorcontrib><creatorcontrib>WITT, P</creatorcontrib><creatorcontrib>LOBUGLIO, A. F</creatorcontrib><creatorcontrib>SALEH, M. N</creatorcontrib><creatorcontrib>SCHLOM, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GREINER, J. W</au><au>GUADAGNI, F</au><au>GOLDSTEIN, D</au><au>BORDEN, E. C</au><au>RITTS, R. E</au><au>WITT, P</au><au>LOBUGLIO, A. F</au><au>SALEH, M. N</au><au>SCHLOM, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence for the elevation of serum carcinoembryonic antigen and tumor associated glycoprotein-72 levels in patients administered interferons</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1991-08-15</date><risdate>1991</risdate><volume>51</volume><issue>16</issue><spage>4155</spage><epage>4163</epage><pages>4155-4163</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Sera were collected from 111 patients diagnosed with adenocarcinoma or nonadenocarcinoma malignancies who received different schedules of interferon (IFN)-gamma or IFN-beta ser alone or in combination. Serum carcinoembryonic antigen (CEA) and tumor-associated glycoprotein-72 (TAG-72) antigen levels were measured to determine whether interferon could enhance the tumor shedding and, thereby, the serum level of either tumor antigen. Less than 10% of the sera samples from patients diagnosed with nonadenocarcinoma malignancies (e.g., hairy cell leukemia, melanoma) had positive titers of TAG-72 or CEA, and interferon neither increased nor resulted in the appearance of either tumor antigen in those sera. In contrast, 59.2% and 75.4% of the patients with adenocarcinoma had positive serum levels of TAG-72 and CEA, respectively, prior to interferon. IFN-gamma and IFN-beta ser alone or in combination significantly increased serum TAG-72 or CEA in approximately 65% of those patients. The results suggest that interferon administration to patients with adenocarcinoma can result in increased serum levels of selected tumor-associated antigens used in the diagnosis of malignancy. These preliminary findings may be important in the development of new strategies to obtain more sensitive tumor antigen serum assays for the diagnosis and monitoring for disease progression of adenocarcinoma.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>1907881</pmid><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 1991-08, Vol.51 (16), p.4155-4163
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_80732868
source MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals
subjects Adenocarcinoma - blood
Adenocarcinoma - immunology
Adenocarcinoma - therapy
Antigens, Neoplasm - analysis
Antineoplastic agents
Biological and medical sciences
Biomarkers, Tumor - blood
Carcinoembryonic Antigen - analysis
Female
Glycoproteins - analysis
Humans
Immunotherapy
Interferon Type I - therapeutic use
Interferon-gamma - therapeutic use
Medical sciences
Neoplasms - blood
Neoplasms - immunology
Neoplasms - therapy
Pharmacology. Drug treatments
title Evidence for the elevation of serum carcinoembryonic antigen and tumor associated glycoprotein-72 levels in patients administered interferons
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T02%3A19%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence%20for%20the%20elevation%20of%20serum%20carcinoembryonic%20antigen%20and%20tumor%20associated%20glycoprotein-72%20levels%20in%20patients%20administered%20interferons&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=GREINER,%20J.%20W&rft.date=1991-08-15&rft.volume=51&rft.issue=16&rft.spage=4155&rft.epage=4163&rft.pages=4155-4163&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E80732868%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16151650&rft_id=info:pmid/1907881&rfr_iscdi=true